Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma.
Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma.
复制标题
DOI：
10.1007/s11307-010-0445-3
复制
发表时间：
2011-12
影响因子：
3.1
通讯作者：
Goodman, Mark M.
中科院分区：
文献类型：
--
作者：
Savir-Baruch, Bital;Schuster, David M.;Jarkas, Nashwa;Master, Viraj A.;Nieh, Peter T.;Halkar, Raghuveer K.;Nye, Jonathon A.;Lewis, Melinda M.;Crowe, Ronald J.;Voll, Ronald J.;Camp, Vernon M.;Bellamy, Leah M.;Roberts, David L.;Goodman, Mark M.
Anti-1-amino-2-[18F]fluorocyclopentane-1-carboxylic酸(抗2-[18F]FACPC)是一种非天然的脂环氨基酸放射性示踪剂，在体外对DU-145前列腺癌细胞具有高摄取率。我们的目标是确定抗2-[18F]FACPC在前列腺癌检测中是否有用。5例前列腺癌根治术后PSA升高(1.1~20.5 ng/mL)的患者，静脉注射193~340MBq的抗2-[18F]FACPC后60min行盆腔动态正电子发射断层扫描(PET)。在相似的时间点，将亮氨酸类似物anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic酸(抗[18F]FACBC)的摄取与正电子发射计算机断层扫描进行比较，并通过病理、临床和成像随访进行验证。在5分钟时，抗2-[18F]FACPC和抗[18F]FACBC的恶性病变的平均(±SD)SUVmax分别为4.1(±1.3)和4.3(±1.1)。然而，抗2-[18F]FACPC在5分钟时的血池活性显著高于抗[18F]FACBC，平均(±SD)病变/血池SUVmax/SUV平均值为1.4(±0.5)比3.0(±0.9)。在20min时，抗2-[18F]FACPC和抗[18F]FACBC的恶性病变的平均(±SD)SUVmax分别为2.6(±1.0)和3.4(±0.8)。然而，在20分钟时，抗2-[18F]FACPC的膀胱活动明显更强烈，平均(±SD)病变/膀胱SUVmax/SUV的比率为0.3(±0.8)比抗[18F]FACBC的2.3(±1.4)。虽然在抗2-[18F]FACPC的早期成像中可以看到前列腺床病变，但有高血池活动遮盖结节。随着血池的消退，结节摄取减少，高膀胱活动继而遮盖骨盆结构。与抗[18F]FACBC相比，抗-2-[18F]FACPC的影像特征不利于盆腔复发前列腺癌的检测。
Anti-1-amino-2-[18F]fluorocyclopentane-1-carboxylic acid (anti-2-[18F]FACPC) is an unnatural alicyclic amino acid radiotracer with high uptake in the DU-145 prostate cancer cell line in vitro. Our goal was to determine if anti-2-[18F]FACPC is useful in the detection of prostate carcinoma. Five patients with elevated PSA (1.1–20.5 ng/mL) after curative therapy for prostate carcinoma underwent 60 min dynamic positron emission tomography (PET) of the pelvis after IV injection of 193–340 MBq of anti-2-[18F]FACPC. Uptake was compared against PET scans in the same patients with the leucine analog, anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC), at similar time points and validated via pathology, clinical, and imaging follow-up. At 5 min, average (±SD) SUVmax of malignant lesions is 4.1(±1.3) for anti-2-[18F] FACPC and 4.3(±1.1) for anti-[18F]FACBC. Yet, blood pool activity at 5 min is significantly higher for anti-2-[18F]FACPC with average (±SD) lesion/blood pool SUVmax/SUVmean ratio of 1.4 (±0.5) vs. 3.0 (±0.9) for anti-[18F]FACBC. At 20 min, average (±SD) SUVmax of malignant lesions is 2.6 (±1.0) for anti-2-[18F]FACPC and 3.4 (±0.8) for anti-[18F]FACBC. Yet, bladder activity at 20 min is significantly more intense for anti-2-[18F] FACPC with average (±SD) lesion/bladder SUVmax/SUVmean ratio of 0.3 (±0.8) vs. 2.3 (±1.4) for anti-[18F]FACBC. While prostate bed lesions are visible on early imaging with anti-2-[18F]FACPC, there is high blood pool activity obscuring nodes. As blood pool fades, nodal uptake decreases and high bladder activity then obscures pelvic structures. Compared with anti-[18F]FACBC, imaging characteristics for anti-2-[18F]FACPC are unfavorable for pelvic recurrent prostate carcinoma detection.
影响因子：
6.6
作者：
Tóth, G;Lengyel, Z;Tóth, C
通讯作者：
Tóth, C